Fusion Pharmaceuticals Announces Appointment of John J. Crowley as Chief Financial Officer

, a clinical-stage biopharmaceutical company
developing targeted alpha-particle radiotherapeutics for treating
cancer, today announced the appointment of John J. Crowley as Chief
Financial Officer. In this position, Mr. Crowley will lead Fusion’s
finance function, reporting to John Valliant, Ph.D., Chief Executive
Officer of Fusion Pharmaceuticals.

“I am pleased to welcome John to the Fusion team at this exciting time
in the Company’s evolution, as we advance our lead program, FPI-1434, in
the clinic,” said John Valliant, Ph.D., CEO of Fusion. “John’s proven
leadership and experience in building global finance organizations to
support aggressive growth will be critical, as Fusion progresses its
targeted alpha-particle radiotherapeutic platform across multiple
indications in oncology.”

Mr. Crowley brings to Fusion over 20 years of global biotechnology
financial and operational experience. Most recently, he served as
Executive Vice President and Chief Financial Officer at Merus, Inc.,
where he led the finance and investor relations functions and was
instrumental in the build-out of the company’s U.S. and global
operations. Prior to joining Merus, Mr. Crowley served as Corporate
Senior Vice President, Corporate Controller and Chief Accounting Officer
of Charles River Laboratories, Inc. Previously, he served as Vice
President, Corporate Controller and Chief Accounting Officer of Ironwood
Pharmaceuticals, Inc. and held senior corporate finance positions at
Vertex Pharmaceuticals, Inc. and Sunovion Pharmaceuticals, Inc. Mr.
Crowley is a Certified Public Accountant and graduated Summa Cum Laude
from Babson College with B.S. degrees in both Economics and Accountancy.

“I am honored to join such a talented leadership team as it pioneers a
unique and powerful radiotherapeutic platform with a vision of
developing innovative medicines for the treatment of cancer,” said John
J. Crowley. “We have a unique opportunity to improve the lives of
patients, and I look forward to working with the team to advance these
scientific breakthroughs and help contribute to our continued success.”

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company
located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming
the leader in the targeted alpha therapy field. Fusion will exploit its
unique expertise in linking medical isotopes to targeting molecules, via
its proprietary Fast-ClearTM Technology
Platform, to create highly effective therapeutics. In addition to its
lead program, FPI-1434, which had its first patient dosed in a Phase I
trial in February 2019, Fusion is expanding its pipeline of products
through a proprietary protein discovery platform, in-licensing targeting
molecules, and forming new strategic partnerships. For more information,
please visit www.fusionpharma.com or
contact info@fusionpharma.com.


Fusion Pharmaceuticals
Lynn Wick

error: Content is protected !!